Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease

Bibliography

• TONTONOZ P, HU E, SPIEGELMAN BM: Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell (1994) 79:1147-1156.
   PubMed Web of Science ®Google Scholar
• WAHLI W, BRAISSANT O, DESVERGNE B: Peroxisome proliferators-activated receptor. Transcriptional regulators of adipogenesis, lipid metabolism and more? Chem. Biol. (1995) 2:261-266.
   PubMed Web of Science ®Google Scholar
• AMRI EZ, BONINO F, AILHAUD G, ABUMRAD NA, GRIMALDI PA: Cloning of a protein that mediated transcriptional effects of fatty acids in preadipocytes. J. Biol. Chem. (1995) 270:2367-2371.
   PubMed Web of Science ®Google Scholar
• ISSEMANN I, GREEN S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 347:647-650.
   Google Scholar
• KLIEWER SA, FORMAN BM, BLUMBERG B et al.: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA (1994) 91:7355-7359.
   PubMed Web of Science ®Google Scholar
• ROSENFIELD RL, DEPLEWSKI D, GREENE ME: Peroxisome proliferator-activated receptors and skin development. Hormone Res. (2000) 54:269-274.
   PubMed Web of Science ®Google Scholar
• NOLTE RT, WISELY GB, WESTIN S et al.: Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature (1998) 395:137-143.
   PubMed Web of Science ®Google Scholar
• KREY G, BRAISSANT O, L’HORSET F et al.: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. (1997) 11:779-791.
   PubMed Web of Science ®Google Scholar
• BERGER J, MOLLER DE: The mechanisms of action of PPARs. Ann. Rev. Med. (2002) 53:409-435.
   Web of Science ®Google Scholar
• MIYATA KS, McCAW SE, MARCUS SL et al.: The peroxisome proliferator-activated receptor interacts with the retinoid X receptor in vivo. Gene (1994) 148:327-330.
   PubMed Web of Science ®Google Scholar
• McKENNA NJ, O’MALLEY BW: Combinatorial control of gene expression by nuclear receptors and coregulators. Cell (2002) 108:465-474.
   PubMed Web of Science ®Google Scholar
• HORLEIN AN, NAAR AM, HEINZEL T et al.: Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature (1995) 377:397-404.
   PubMed Web of Science ®Google Scholar
• CHEN JD, UMESONO K, EVANS RM: SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. Proc. Natl. Acad. Sci. USA (1996) 93:7567-7571.
   Google Scholar
• IJPENBERG A, TAN NS, GELMAN L et al.: In vivo activation of PPAR target genes by RXR homodimers. EMBO J. (2004) 23:2083-2091.
   PubMed Web of Science ®Google Scholar
• MANDARD S, ZANDBERGEN F, TAN NS et al.: The direct perxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J. Biol. Chem. (2004) 279:34411-34420.
   PubMed Web of Science ®Google Scholar
• JIA Y, QI C, KASHIREDDI P et al.: Transcription coactivator PBP, the peroxisome proliferator-activated receptor (PPAR)-binding protein, is required for PPAR α-regulated gene expression in liver. J. Biol. Chem. (2004) 279:24427-24434.
   PubMed Web of Science ®Google Scholar
• COMPE E, DRANE P, LAURENT C et al.: Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations. Mol. Cell. Biol. (2005) 25:6065-6076.
   PubMed Web of Science ®Google Scholar
• PASCUAL G, FONG AL, OGAWA S et al.: A sumoylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature (2005) 437:759-763.
   PubMed Web of Science ®Google Scholar
• GIZARD F, AMANT C, BARBIER O et al.: PPAR α inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J. Clin. Invest. (2005) 115:3228-3238.
   PubMed Web of Science ®Google Scholar
• GUAN HP, ISHIZUKA T, CHUI PC et al.: Corepressors selectively control the transcriptional activity of PPARγ in adipocytes. Gene Dev. (2005) 19:453-461.
   PubMed Web of Science ®Google Scholar
• CHUI PC, GUAN HP, LEHRKE M, LAZAR MA: PPARγ regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1. J. Clin. Invest. (2005) 115:2244-2256.
   PubMed Web of Science ®Google Scholar
• FU M, RAO M, BOURAS T et al.: Cyclin D1 inhibits peroxisome proliferator-activated receptor γ-mediated adipogenesis through histone deacetylase recruitment. J. Biol. Chem. (2005) 280:16934-16941.
   PubMed Web of Science ®Google Scholar
• SEREE E, VILLARD PH, PASCUSSI JM et al.: Evidence for a new human CYP1A1 regulation pathway involving PPAR-α and 2 PPRE sites. Gastroenterology (2004) 127:1436-1445.
   PubMed Web of Science ®Google Scholar
• SHIMIZU M, TAKESHITA A, TSUKAMOTO T, GONZALEZ FJ, OSUMI T: Tissue-selective, bidirectional regulation of PEX11 α and perilipin genes through a common peroxisome proliferator response element. Mol. Cell. Biol. (2004) 24:1313-1323.
   PubMed Web of Science ®Google Scholar
• FEIGE JN, GELMAN L, MICHALIK L, DESVERGNE B, WAHLI W: From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res. (2006) 45:120-159.
   PubMed Web of Science ®Google Scholar
• ZHU Y, ALVARES K, HUANG Q, RAO MS, REDDY JK: Cloning of new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J. Biol. Chem. (1993) 268:26817-26820.
   PubMed Web of Science ®Google Scholar
• GREENE ME, BLUMBERG B, McBRIDE OW et al.: Isolation of the human peroxisome proliferator activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. (1995) 4:281-299.
   PubMedGoogle Scholar
• ELBRECHT A, CHEN Y, CULLINAN CA et al.: Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ 1 and γ 2. Biochem. Biophys. Res. Commun. (1996) 224:431-437.
   Google Scholar
• LAMBE KG, TUGWOOD JD: A human peroxisome proliferator activated receptor-γ is activated by inducers of adipogenesis including thiazolidinedione drugs. Eur. J. Biochem. (1996) 239:1-7.
   Google Scholar
• FAJAS L, AUBOEUF D, RASPE E et al.: The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem. (1997) 272:18779-18789.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE R, JOW L, CROSTON GE, PATERNITI JR Jr: Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem. (1997) 272:8071-8076.
   PubMed Web of Science ®Google Scholar
• FAJAS L, FRUCHART JC, AUWERX J: PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett. (1998) 438:55-60.
   PubMed Web of Science ®Google Scholar
• LEHMANN JM, MOORE LB, SMITH-OLIVER TA et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J. Biol. Chem. (1995) 270:12953-12956.
   PubMed Web of Science ®Google Scholar
• HULIN B, McCARTHY PA, GIBBS EM: The glitazones family of antidiabetic agents. Curr. Pharm. Des. (1996) 2:85-102.
   Web of Science ®Google Scholar
• FUJITA T, SUGIYAMA Y, TAKETOMI S et al.: Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]- thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes (1983) 32:804-810.
   PubMed Web of Science ®Google Scholar
• BERGER J, BAILEY P, BISWAS C et al.: Thiazolidinediones produce a conformational change in peroxisome proliferator-activated receptor-γ: binding and activation correlate with antidiabetic action in db/db mice. Endocrinology (1996) 137:4189-4195.
   PubMed Web of Science ®Google Scholar
• WILLSON TM, COBB JE, COWAN DJ et al.: The structure–activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. (1996) 39:665-668.
   PubMed Web of Science ®Google Scholar
• SOHDA T, MIZUNO K, KAWAMATSU Y: Studies on antidiabetic agents VI. Asymmetric transformation of (±)–5[4(1-methylcyclohexylmethoxy)- benzyl]-2,4-thiazolidinedione (ciglitazone) with optically active 1-phenylethylamines. Chem. Pharm. Bull. (1984) 32:4460-4465.
   PubMed Web of Science ®Google Scholar
• DAVIES GF, McFIE PJ, KHANDELWAL RL, ROESLER WJ: Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-γ expression in hepatocytes. J. Pharmacol. Exp. Ther. (2002) 300:72-77.
   Google Scholar
• VENKATRAMAN MS, CHITTIBOYINA A, MEINGASSNER J et al.: α-lipoic acid-based PPAR γ agonists for treating inflammatory skin diseases. Arch. Dermatol. Res. (2004) 296:97-104.
   PubMed Web of Science ®Google Scholar
• HENKE BR, BLANCHARD SG, BRACKEEN MF et al.: N-(2-benzoylphenyl)-l-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem. (1998) 41:5020-5036.
   PubMed Web of Science ®Google Scholar
• COLLINS JL, BLANCHARD SG, BOSWELL GE et al.: N-(2-benzoylphenyl)-l-tyrosine PPARγ agonists. 2. Structure–activity relationship and optimization of the phenyl alkyl moeity. J. Med. Chem. (1998) 41(25):5037-5054.
   Google Scholar
• COBB JE, BLANCHARD SG, BOSWELL EG et al.: N-(2-benzoylphenyl)-l-tyrosine PPARγ agonists. 3. Structure–activity relationship and optimization of the N-aryl substituent. J. Med. Chem. (1998) 41:5055-5069.
   PubMed Web of Science ®Google Scholar
• LEHMANN JM, LENHARD JM, OLIVER BB, RINGOLD GM, KLIEWER SA: Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. (1997) 272:3406-3410.
   PubMed Web of Science ®Google Scholar
• XU HE, LAMBERT MH, MONTANA VG et al.: Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell (1999) 3:397-403.
   PubMed Web of Science ®Google Scholar
• FORMAN BM, TONTONOZ P, CHEN J et al.: 15-Deoxy-δ 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ. Cell (1995) 83:803-812.
   PubMed Web of Science ®Google Scholar
• KLIEWER SA, LENHARD JM, WILLSON TM et al.: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell (1995) 83:813-819.
   PubMed Web of Science ®Google Scholar
• DANG ZC, AUDINOT V, PAPAPOULOS SE, BOUTIN JA, LOWIK CW: Peroxisome proliferator-activated receptor γ (PPAR γ) as a molecular target for the soy phytoestrogen. (2003) 278(2):962-967.
   Google Scholar
• SCHOPFER FJ, LIN Y, BAKER PR et al.: Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand. Proc. Natl. Acad. Sci. USA (2005) 102:2340-2345.
   Google Scholar
• BAKER PR, LIN Y, SCHOPFER FJ et al.: Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J. Biol. Chem. (2005) 280:42464-42475.
   PubMed Web of Science ®Google Scholar
• SARRAF P, MUELLER E, JONES D et al.: Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med. (1998) 4:1046-1052.
   Google Scholar
• MUELLER E, SARRAF P, TONTONOZ P et al.: Terminal differentiation of human breast cancer through PPAR γ. Mol. Cell (1998) 1:465-470.
   Google Scholar
• KUBOTA T, KOSHIZUKA K, WILLIAMSON EA et al.: Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. (1998) 58:3344-3352.
   PubMed Web of Science ®Google Scholar
• KITAMURA S, YIYAZAKI Y, SHINOMURA Y et al.: Peroxisome proliferator-activated receptor-γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn J. Cancer Res. (1999) 90:75-80.
   Google Scholar
• ELSTNER E, MULLER C, KOSHIZUKA K et al.: Ligands for peroxisome proliferators-activated receptor γ and retinoic acid receptor inhibit growth and induce apopotosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA (1998) 95:8806-8811.
   PubMed Web of Science ®Google Scholar
• SARRAF P, MUELLER E, SMITH WM et al.: Loss of function mutations in PPAR-γ associated with human colon cancer. Mol. Cell (1999) 3:799-804.
   PubMed Web of Science ®Google Scholar
• NAKASHIRO K-I, HAYASHI Y, KITA A et al.: Role of peroxisome proliferator-activated receptor γ and its ligands in non-neoplastic and neoplastic human urothelial cells. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Am. J. Pathol. (2001) 159:591-597.
   PubMed Web of Science ®Google Scholar
• TONTONOZ P, SINGER S, FORMAN BM et al.: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl. Acad. Sci. USA (1997) 94:237-241.
   Google Scholar
• RUMI MA, ISHIHARA S, KADOWAKI Y et al.: Peroxisome proliferators-activated receptor γ-dependent and -independent growth inhibition of gastrointestinal tumor cells. Genes Cells (2004) 9:1113-1123.
   PubMed Web of Science ®Google Scholar
• ALTIOK S, XU M, SPIEGELMAN BM: PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. (1997) 11:1987-1998.
   PubMed Web of Science ®Google Scholar
• YOSHIZUMI T, OHTA T, NINOMIYA I et al.: Thiazoladinedione, a peroxisome proliferator-activated receptor-γ ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int. J. Oncol. (2004) 25:631-639.
   PubMed Web of Science ®Google Scholar
• LEBOVIC DI, KIR M, CASEY CL: Peroxisome proliferators-activated receptor-γ induces regression of endometrial explants in a rat model of endometriosis. Fertility Sterility (2004) 82(Suppl. 3):1008-1013.
   PubMed Web of Science ®Google Scholar
• CHINETTI G, LESTAVEL S, BOCHER V et al.: PPAR-α and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. (2001) 7:53-58.
   PubMed Web of Science ®Google Scholar
• CHAWLA A, BARAK Y, NAGY L, LIAO D, TONTONOZ P, EVANS RM: PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. (2001) 7:48-52.
   PubMed Web of Science ®Google Scholar
• DESMET C, WARZEE B, GOSSET P et al.: Pro-inflammatory properties for thiazolidinediones. Biochem. Pharmacol. (2005) 69:255-265.
   PubMed Web of Science ®Google Scholar
• GARDNER OS, SHIAU CW, CHEN CS, GRAVES LM: Peroxisome proliferator-activated receptor γ-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress. J. Biol. Chem. (2005) 280:10109-10118.
   PubMed Web of Science ®Google Scholar
• LEA MA, SURA M, DESBORDES C: Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) γ agonists and antagonists. Anti-Cancer Res. (2004) 24:2765-2771.
   PubMed Web of Science ®Google Scholar
• CHEN ZY, HARRISON LE: Ciglitazone induces early cellular proliferation and NF-κB transcriptional activity in colon carcinoma cells through p65 phosphorylation. Int. J. Biochem. Cell Biol. (2005) 37:645-654.
   Web of Science ®Google Scholar
• CHEN ZY, TSENG CC: 15-deoxy-δ 12,14 prostaglandin J2 up-regulates Kruppel-like factor-4 expression independently of peroxisome proliferator-activated receptor-γ by activating mitogen-activated protein kinase in HT-29 colon carcinoma cells. Mol. Pharmacol. (2005) 68:1203-1233.
   Google Scholar
• KIM CS, PARK WH, PARK JY et al.: Capsaicin, a spicy component of hot pepper, induces apoptosis by activation of the peroxisome proliferators-activated receptor γ in HT-29 human colon carcinoma cells. J. Med. Food. (2004) 7:267-273.
   PubMed Web of Science ®Google Scholar
• ULRICH S, WACHTERSHAUSER A, LOITSCH S et al.: Activation of PPARγ is not involved in butyrate-induced epithelial cell differentiation. Exp. Cell Res. (2005) 310:196-204.
   PubMed Web of Science ®Google Scholar
• RIVIER M, SAFONOVA I, LEBRUN P et al.: Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J. Invest. Dermatol. (1998) 111:1116-1121.
   PubMed Web of Science ®Google Scholar
• MAO-QIANG M, FOWLER AJ, SCHMUTH M et al.: Peroxisome-proliferator-activated receptor (PPAR)-γ activation stimulates keratinocyte differentiation. J. Invest. Dermatol. (2004) 123:305-312.
   PubMed Web of Science ®Google Scholar
• KOMUVES LG, HANLEY K, JIANG Y et al.: Ligands and activators of nuclear hormone receptors regulate epidermal differentiation during fetal rat skin development. J. Invest. Dermatol. (1998) 111:429-433.
   PubMed Web of Science ®Google Scholar
• WESTERGAARD M, HENNINGSEN J, SVENDSEN ML et al.: Modulation of keratinocyte gene expression and differentiation by ppar-selective ligands and tetradecylthioacetic acid. J. Invest. Dermatol. (2001) 116:702-712.
   PubMed Web of Science ®Google Scholar
• WESTERGAARD M, HENNINGSEN J, JOHANSEN C: Expression and localization of peroxisome proliferator-activated receptors and nuclear factor κB in normal and lesional psoriatic skin. J. Invest. Dermatol. (2003) 121:1104-1117.
   PubMed Web of Science ®Google Scholar
• GHOSH AK, BHATTACHARYYA S, LAKOS G et al.: Disruption of transforming growth factor β signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor γ. Arthritis Rheum. (2004) 50:1305-1318.
   PubMed Web of Science ®Google Scholar
• KANG HY, CHUNG E, LEE M, CHO Y, KANG WH: Expression and function of peroxisome proliferators-activated receptors in human melanocytes. Br. J. Dermatol. (2004) 150:462-468.
   PubMed Web of Science ®Google Scholar
• ROSENFIELD RL, DEPLEWSKI D, GREENE ME: Peroxisome proliferators-activated receptors and skin development. Hormone Res. (2000) 54:269-274.
   PubMed Web of Science ®Google Scholar
• DI-POI N, MICHALIK L, DESVERGNE B, WAHLI W: Functions of peroxisome proliferators-activated receptors (PPAR) in skin homeostasis. Lipids (2004) 39:1093-1099.
   PubMed Web of Science ®Google Scholar
• KUENZLI S, SAURAT JH: Peroxisome proliferators-activated receptors in cutaneous biology. Br. J. Dermatol. (2003) 149:229-236.
   PubMed Web of Science ®Google Scholar
• GUO YT, LENG XS, PENG JR et al.: Effect of ligand of peroxisome proliferators-activated receptor γ on the biological characters of hepatic stellate cells. World J. Gastroenterol. (2005) 11:4735-4739.
   PubMed Web of Science ®Google Scholar
• HE G, THUILLIER P, FISCHER SM: Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPAR-γ in normal mouse skin keratinocytes. J. Invest. Dermatol. (2004) 123:1110-1119.
   PubMed Web of Science ®Google Scholar
• KOMUVES LG, HANLESY K, LEFEBVRE A-M: Stimulation of PPARα promotes epidermal keratinocyte differentiation in vivo. J. Invest. Dermatol. (2000) 115:353-360.
   PubMed Web of Science ®Google Scholar
• SCHMUTH M, HAQQ CM, CAIRNS WJ: Peroxisome proliferators-activated receptor (PPAR) β/δ stimulates differentiation and lipid accumulation in keratinocytes. J. Invest. Dermatol. (2004) 122:971-983.
   PubMed Web of Science ®Google Scholar
• HE G, MUGA S, THUILLIER P, LUBET RA, FISCHER SM: The effect of PPARγ ligands on UV- or chemically-induced carcinogenesis in mouse skin. Mol. Carcinogen. (2005) 43:198-206.
   Google Scholar
• ELLIS CN, VARANI J, FISHER GJ et al.: Troglitazone improves psoriasis and normalizes models of proliferative skin disease. Arch. Dermatol. (2000) 136:609-615.
   PubMed Web of Science ®Google Scholar
• BHAGAVATHULA N, NERUSU KC, LAL A et al.: Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J. Invest. Dermatol. (2004) 122:130-139.
   PubMed Web of Science ®Google Scholar
• BHAGAVATHULA N, NERUSU K, REDDY M et al.: BP-1007: a novel synthetic thiazoladinedione that inhibits epidermal hyperplasia in psoriatic skin – SCID mouse transplants following topical application. J. Pharmacol. Exp. Therapeut. (2005) 315:996-1004.
   PubMed Web of Science ®Google Scholar
• DUELL EA, ASTROM A, GRIFFITHS CE, CHAMBON P, VOORHEES JJ: Human skin levels of retinoic acid and P450-derived 4-hydroxyretinoic acid after topical application of retinoic acid in vivo compared to the concentrations required to stimulate retinoic acid receptor-mediated gene transcription in vitro. J. Clin. Invest. (1992) 90:1269-1274.
   PubMed Web of Science ®Google Scholar
• VARANI J, INMAN DR, PERONE P, FLIGIEL SEG, VOORHEES JJ: Retinoid toxicity of fibroblasts and epithelial cells is separable from growth-promoting activity. J. Invest. Dermatol. (1993) 101:839-842.
   PubMed Web of Science ®Google Scholar
• NICKOLOFF BJ, MITRA RS, RISER BL, DIXIT VM, VARANI J: Modulation of keratinocyte motility; correlation with production of extracellular matrix molecules in response to growth promoting and anti-proliferative factors. Am. J. Path. (1988) 132:543-551.
   Web of Science ®Google Scholar
• PILCHER BK, DUMIN JA, SUDBECK BD et al.: The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J. Cell Biol. (1997) 137:1445-1457.
   PubMed Web of Science ®Google Scholar
• GRZESIAK JJ, PIERSCHBACHER MD: Shifts in the concentrations of magnesium and calcium in early porcine and rat wound fluid activate the cell migratory response. J. Clin. Invest. (1995) 95:227-233.
   PubMed Web of Science ®Google Scholar
• VARANI J, FLIGIEL SE, SCHUGER L et al.: Effects of all-trans retinoic acid and ca++ on human skin in organ culture. Am. J. Pathol. (1993) 142:189-198.
   PubMed Web of Science ®Google Scholar
• VARANI J, PERONE P, GRIFFITHS C et al.: All-trans retinoic acid stimulates events in organ cultured human skin that underlie repair. J. Clin. Invest. (1994) 94:1747-1756.
   PubMed Web of Science ®Google Scholar
• KONDO S: Maintenance of epidermal structure of psoriatic skin in organ culture. J. Dermatol. (1986) 13:242-249.
   PubMedGoogle Scholar
• KONDO S, HOZUMI Y, MAEJIMA H, ASO K: Organ culture of psoriatic skin: effect of TGF-α and TGF-β on epidermal structure in vitro. Arch. Dermatol. Res. (1992) 284:150-153.
   PubMed Web of Science ®Google Scholar
• VARANI J, KANG S, STOLL S, ELDER JT: Human psoriatic skin in organ culture: comparison with normal skin exposed to exogenous growth factors and effects of an antibody to the EGF receptor. Pathobiology (1988) 66:253-259.
   Google Scholar
• GILHAR A, DAVID M, ULLMANN Y, BERKUTSKI T, KALISH RS: T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J. Invest. Dermatol. (1997) 109:283-288.
   PubMed Web of Science ®Google Scholar
• ZEIGLER M, CHI Y, TUMAS DB et al.: Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with cyclosporin A and clobetasol propionate. Lab. Invest. (2001) 81:1253-1261.
   PubMed Web of Science ®Google Scholar
• DAM TM, KANG S, NICKOLOFF BJ, VOORHEES JJ: 125-dihydroxycholecalciferol and cyclosporin suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to scid mice. J. Invest. Dermatol. (1999) 113:1082-1089.
   PubMed Web of Science ®Google Scholar
• VILLADSEN LS, SCHUURMAN J, BEURSKENS F et al.: Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J. Clin. Invest. (2003) 112:1571-1580.
   PubMed Web of Science ®Google Scholar
• ELDER JT, FISHER GJ, LINDQUIST PB, VOORHEES JJ: Overexpression of transforming growth factor-α in psoriatic epidermis. Science (1989) 243:811-814.
   PubMed Web of Science ®Google Scholar
• VARANI J, ZEIGLER M, DAME MK et al.: HB-EGF activation of keratinocyte ErbB receptors mediates epidermal hyperplasia, a prominent side effect of retinoid therapy. J. Invest. Dermatol (2001) 117:1335-1341.
   PubMed Web of Science ®Google Scholar
• RITTIÉ L, VARANI J, KANG S, FISHER GJ, VOORHEES JJ: Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligand heparin binding-EGF and amphiregulin in human skin in vivo. J. Invest. Dermatol. (2006) 126:732-739.
   PubMed Web of Science ®Google Scholar
• BHAGAVATHULA N, NERUSU KC, FISHER GJ et al.: Amphiregulin and epidermal hyperplasia: amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on SCID mice. Am. J. Pathol. (2005) 166:1009-1016.
   Web of Science ®Google Scholar
• PITTELKOW MR, COOK PW, SHIPLEY GD, DERYNCK R, COFFEY RJ Jr: Autonomous growth of human keratinocytes requires epidermal growth factor receptor occupancy. Cell Growth Differ. (1993) 4:513-521.
   PubMedGoogle Scholar
• VALDIMARSSON H, BAKER BS, JONSDOTTIR I, POWLES A, FRY L: Psoriasis: a T-cell mediated autoimmune disease mediated by streptococcal superantigen? Immunol. Today (1996) 16:145-149.
   Google Scholar
• AUSTIN LM, OZAWA M, KIKUCHI T, WALTERS IB, KUEUGER JG: The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines – interferon-γ, interelukin-2 and tumor necrosis factor-α – defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias also measured in circulating blood T cells in psoriasis patients. J. Invest. Dermatol. (1999) 113:101-108.
   Google Scholar
• COOK PW, PIEPKORN M, CLEGG CH et al.: Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J. Clin. Invest. (1997) 100:2286-2294.
   PubMed Web of Science ®Google Scholar
• COOK PW, BROWN JR, CORNELL KA, PITTELKOW MR: Suprabasal expression of human amphiregulin in the epidermis of transgenic mice induces a severe, early-onset, psoriasis-like skin pathology: expression of amphiregulin in the basal epidermis is also associated with synovitis. Exp. Dermatol. (2004) 13:347-356.
   PubMed Web of Science ®Google Scholar
• DENDA M, WOOD LC, EMAMI S: The epidermal hyperplasia associated with repeated barrier disruption by acetone treatment or tape-stripping cannot be attributed to increased water loss. Arch. Dermatol. Res. (1996) 288:230-238.
   Google Scholar
• VARANI J, FLIGIEL H, ZHANG J et al.: Separation of retinoid-induced epidermal and dermal thickening from skin irritation. Arch. Dermatol. Res. (2003) 295:255-262.
   PubMed Web of Science ®Google Scholar
• DEMERJIAN M, MAN M-Q, CHOI E-H et al.: Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-γ, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp. Dermatol. (2006) 15:154-160.
   PubMed Web of Science ®Google Scholar
• KOMUVES LG, SCHMUTH M, FOWLER AJ: Oxysterol stimulation of epidermal differentiation is mediated by liver X receptor-β in murine epidermis. J. Invest. Dermatol. (2002) 118:25-34.
   PubMed Web of Science ®Google Scholar
• SCHMUTH M, HAQQ CM, CAIRNS WJ: Peroxisome proliferator-activated receptor (PPAR)-β/δ stimulates differentiation and lipid accumulation in keratinocytes. J. Invest. Dermatol. (2004) 122:971-983.
   PubMed Web of Science ®Google Scholar
• KLEMKE RL, CAI S, GIANNINI AL et al.: Regulation of cell motility by mitogen-activated protein kinase. J. Cell Biol. (1997) 137:481-492.
   PubMed Web of Science ®Google Scholar
• RESZKA A, SEGER R, KREBS E, FISCHER E: Association of mitogen-activated protein kinase wih the microtubule cytoskeleton. Proc. Natl. Acad. Sci. USA (1995) 92:8881-8885.
   PubMed Web of Science ®Google Scholar
• ZEIGLER ME, CHI Y, SCHMIDT T, VARANI J: Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J. Cell. Physiol. (1998) 180:271-284.
   Web of Science ®Google Scholar
• FISHER GJ, DATTA S, WANG Z et al.: C-jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J. Clin. Invest. (2000) 106:663-670.
   PubMed Web of Science ®Google Scholar
• BRAUCHIE M, GLUCK D, DI PADOVA F, HAN J, GRAM H: Independent role of p38 and ERK1/2 mitogen-activated protein kinases in the upregulation of matrix metalloproteinase-1. Exp. Cell Res. (2000) 258:135-144.
   PubMed Web of Science ®Google Scholar
• WESTERMARCK J, HOLMSTROM T, AHONEN M, ERIKSSON JE, KAHARI VM: Enhancement of fibroblast collagenase-1 (MMP-1) gene expression by tumor promoter okadaic acid is mediated by stress-activated protein kinases and p38. Matrix Biol. (1998) 17:547-557.
   PubMed Web of Science ®Google Scholar
• KORINEK V, BARKR N, MORIN PJ et al.: Constitutive transcriptional activation by a β-catenin–Tcf complex in APC-/- colon carcinoma. Science (1997) 275:1784-1787.
   PubMed Web of Science ®Google Scholar
• VAN AKEN E, DE WEVER O, CORRIEGA DA, ROCHA AS, MAREEL M: Defective E-cadherin/catenin complexes in human cancer. Virchows Arch. (2001) 439:725-751.
   PubMed Web of Science ®Google Scholar
• SHARMA C, PRADEEP A, WONG L, RANA A, RANI B: Peroxisome proliferators-activated receptor γ activation can regulate β-catenin levels via a proteosome-mediated and adenomatous polyposis coli-independent pathway. J. Biol. Chem. (2004) 279:35583-35594.
   PubMed Web of Science ®Google Scholar
• SCHAEFER KL, WADA K, TAKAHASHI H et al.: Peroxisome proliferator-activated receptor-γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res. (2005) 65:2251-2259.
   PubMed Web of Science ®Google Scholar
• YOSHIZUMI T, OHTA T, NINOMIYA I et al.: Thiazolidinedione, a peroxisome proliferators-activated receptor-γ ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int. J. Oncol. (2004) 25:631-639.
   Web of Science ®Google Scholar
• SANDER HM, MORRIS LF, PHILLIPS CM, HARRISON PE, MENTER A: The annual cost of psoriasis. J. Am. Acad. Dematol. (1993) 128:422-425.
   Web of Science ®Google Scholar
• WEISS SC, KIMBALL AB, LIEWEHR DJ et al.: Quantifying the harmful effect of psoriasis on health-related quality of life. J. Am. Acad. Dermatol. (2002) 47:512-518.
   PubMed Web of Science ®Google Scholar
• WONG RL, WINSLOW CM, COOPER KD: The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol. Today (1993) 14:69-74.
   PubMedGoogle Scholar
• GREAVES MW, WEINSTEIN GD: Treatment of psoriasis. N. Engl. J. Med. (1995) 332:581-588.
   PubMed Web of Science ®Google Scholar
• LI LY, BRIMHALL AK, MENTER A: Systemic therapy for moderate to severe psoriasis. Exp. Rev. Dermatol. (2006) 1:77-92.
   Google Scholar
• PERSHADSINGH HA, SPROUL JA, BENJAMIN E, FINNEGAN JA, AMIN NM: Treatment of psoriasis with troglitazone therapy (letter). Arch. Dermatol. (1998) 134:1304-1305.
   PubMed Web of Science ®Google Scholar
• PERSHADSINGH HA, BENSON SC, ELLIS CN: Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. Skinmed. (2005) 4:386-390.
   PubMedGoogle Scholar
• ROBERTSHAW H. FRIEDMANN PS: Pioglitazone: a promising therapy for psoriasis. Br. J. Dermatol. (2005) 152:189-191.
   PubMed Web of Science ®Google Scholar
• SHAFIQ N, MALHOTRA S, PANDHI P et al.: Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int. J. Dermatol. (2005) 44:328-333.
   PubMed Web of Science ®Google Scholar
• MALHOTRA S, BANSAL D, SHAFIQ N, PANDHI P, KUMAR B: Potential therapeutic role of peroxisome proliferator activated receptor-γ agonists in psoriasis. Expert Opin. Pharmacother. (2005) 6:1455-1461.
   PubMed Web of Science ®Google Scholar
• KUENZLI S, SAURAT J-H: Effect of topical PPAR-β/δ and PPARγ agonists on plaque psoriasis: a pilot study. Dermatology (2003) 206:252-256.
   PubMed Web of Science ®Google Scholar
• MURPHY GJ, HOLDER JC: PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharacol. Sci. (2000) 21:469-474.
   PubMed Web of Science ®Google Scholar
• RICOTE M, LI AC, WILLSON TM et al.: The peroxisome proliferators-activated receptor-γ is a negative regulator of macrophage activation. Nature (1998) 391:79-82.
   PubMed Web of Science ®Google Scholar
• CASTILLO A, TONTONOZ P: Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Ann. Rev. Cell Dev. Biol. (2004) 20:455-480.
   PubMed Web of Science ®Google Scholar